Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 drug overhang. Explore more details here.

Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar. The company expects 2025 adjusted profit to be in the range of $8.

Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30. The orthopedic giant reported sales of $2.02 billion,

Shares of Zimmer Biomet Holdings Inc. ZBH slipped 5.14% to $102.69 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.36% to 6,083.57 and the Dow Jones Industrial Average DJIA falling 0.28% to 44,747.63.